Long-term extension study of nusinersen for spinal muscular atrophy
Part of Brain & nervous system clinical trials.
This study gives an ongoing treatment called nusinersen (brand name Spinraza) to people who have already been in a previous study for spinal muscular atrophy (SMA). The goal is to keep providing the medicine and to check how safe and effective it is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have completed the earlier study called 232SM302
- Must not have used any other SMA treatment after finishing that study
- Must be willing to follow standard care guidelines for SMA, including nutrition and breathing support
- For females who can become pregnant and males of reproductive age, effective birth control is required during the study
- Must be in stable health overall, with no new or worsening medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers continued treatment with the drug nusinersen (brand name Spinraza) for people with spinal muscular atrophy who completed a specific earlier study of this medicine. It aims to keep providing the treatment while monitoring safety and effects over a longer period.
This trial tests a new gene therapy called GC101 given as a one-time injection into the spinal fluid for people with type 2 spinal muscular atrophy (SMA). It may help improve motor function.
This trial investigates how the drug nusinersen (Spinraza) enters the body when given through a small, flexible tube placed in the lower back (ThecaFlex DRx system). It aims to learn how the drug is processed in adults and children with spinal muscular atrophy, which could help make dosing more convenient.
This study looks at how tired you feel during physical activities while being treated with nusinersen (Spinraza) for spinal muscular atrophy (SMA). The goal is to understand how well the treatment helps with daily energy levels.
This study follows the long-term safety of Zolgensma gene therapy in Brazilian children with spinal muscular atrophy (SMA). It helps doctors understand how safe the treatment is over time.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
Hear when a new SMA - Spinal Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.